Counteracting immune-evasive mechanisms driven by oncogenic KRAS sensitizes tumors to immunotherapy, supporting the rationale for combination regimens in NSCLC and other RAS-driven cancers [46,57,67,68]. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.